FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Zhaohui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for its Ketoprofen Patch. The subsidiary plans to initiate Phase III clinical trials for the product in China once all conditions are met.